WealthPLAN Partners LLC Increases Holdings in Danaher Co. (NYSE:DHR)

WealthPLAN Partners LLC boosted its position in Danaher Co. (NYSE:DHR) by 9.3% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 15,643 shares of the conglomerate’s stock after buying an additional 1,327 shares during the period. WealthPLAN Partners LLC’s holdings in Danaher were worth $3,908,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Vanguard Group Inc. boosted its holdings in shares of Danaher by 7.4% in the 1st quarter. Vanguard Group Inc. now owns 60,107,030 shares of the conglomerate’s stock valued at $15,009,928,000 after acquiring an additional 4,163,657 shares during the last quarter. Wellington Management Group LLP boosted its holdings in Danaher by 12.0% in the fourth quarter. Wellington Management Group LLP now owns 27,928,442 shares of the conglomerate’s stock valued at $6,460,966,000 after purchasing an additional 2,998,161 shares during the last quarter. Swedbank AB acquired a new stake in Danaher during the 1st quarter worth about $676,545,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main raised its stake in shares of Danaher by 214.4% during the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 3,073,661 shares of the conglomerate’s stock valued at $711,051,000 after buying an additional 2,096,038 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its stake in shares of Danaher by 10.7% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 16,757,558 shares of the conglomerate’s stock worth $3,876,694,000 after buying an additional 1,619,586 shares during the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Stock Performance

NYSE:DHR opened at $276.06 on Tuesday. Danaher Co. has a twelve month low of $182.09 and a twelve month high of $281.70. The company has a market cap of $199.37 billion, a P/E ratio of 46.79, a P/E/G ratio of 4.48 and a beta of 0.83. The company has a current ratio of 1.43, a quick ratio of 1.04 and a debt-to-equity ratio of 0.33. The company’s 50-day moving average price is $265.25 and its 200-day moving average price is $256.67.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, topping the consensus estimate of $1.57 by $0.15. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The business had revenue of $5.74 billion for the quarter, compared to analysts’ expectations of $5.59 billion. During the same period in the previous year, the firm posted $2.05 EPS. The business’s revenue for the quarter was down 2.9% compared to the same quarter last year. On average, sell-side analysts forecast that Danaher Co. will post 7.59 earnings per share for the current fiscal year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Friday, September 27th will be issued a dividend of $0.27 per share. The ex-dividend date is Friday, September 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.39%. Danaher’s dividend payout ratio is presently 18.31%.

Insider Activity

In other Danaher news, SVP Brian W. Ellis sold 9,600 shares of Danaher stock in a transaction dated Thursday, July 25th. The shares were sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the transaction, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at $5,566,486.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Danaher news, SVP Brian W. Ellis sold 9,600 shares of Danaher stock in a transaction on Thursday, July 25th. The stock was sold at an average price of $275.16, for a total value of $2,641,536.00. Following the sale, the senior vice president now owns 20,230 shares in the company, valued at $5,566,486.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Georgeann Couchara sold 952 shares of the stock in a transaction on Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the transaction, the senior vice president now owns 4,212 shares of the company’s stock, valued at $1,130,374.44. The disclosure for this sale can be found here. In the last quarter, insiders have sold 39,659 shares of company stock valued at $11,042,433. 11.10% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several brokerages recently weighed in on DHR. Stifel Nicolaus lifted their price target on Danaher from $235.00 to $250.00 and gave the company a “hold” rating in a research report on Wednesday, July 24th. Wells Fargo & Company began coverage on shares of Danaher in a research note on Tuesday, August 27th. They issued an “equal weight” rating and a $280.00 target price for the company. Bank of America raised their price target on shares of Danaher from $270.00 to $275.00 and gave the company a “neutral” rating in a research report on Wednesday, July 24th. Robert W. Baird upped their price objective on shares of Danaher from $271.00 to $278.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 24th. Finally, Evercore ISI cut their price target on Danaher from $266.00 to $260.00 and set an “outperform” rating for the company in a research note on Tuesday, July 2nd. Seven analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat, Danaher presently has an average rating of “Moderate Buy” and a consensus target price of $278.94.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.